Phase 3, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Phase of Trial: Phase III
Latest Information Update: 14 Sep 2018
At a glance
- Drugs Dantrolene (Primary)
- Indications Heat stroke
- Focus Registrational; Therapeutic Use
- Sponsors Eagle Pharmaceuticals
- 06 Sep 2018 Status changed from recruiting to completed.
- 19 Aug 2018 Status changed from not yet recruiting to recruiting.
- 25 Jul 2018 Status changed from planning to not yet recruiting.